Trial reportThe Korean journal of internal medicine2022
Cancer risk in Korean patients with gout.
Trial report in The Korean journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Pooled it
- Testing for Causal Association Between Serum Urate, Gout, and Prostatic Cancer in European Males.Gout, urate, and crystal deposition disease · 2025Article
- Serum urate levels and colorectal cancer risk: a prospective cohort study in of the UK biobank and a Mendelian randomization analysis.Discover oncology · 2025Article
- Association between allopurinol and hepatocellular carcinoma: analysis of genetic risk and patient survival.Discover oncology · 2025Article
- Assessing the impact of gout on cancer risk and the role of healthy lifestyles.Frontiers in oncology · 2025Article
- Effect of gout and diabetic kidney disease on renal cancer development in Korea.Clinical kidney journal · 2024Article
- Association of Gout with Head and Neck Cancer: Longitudinal Follow-Up Studies Using a National Health Insurance Database in South Korea.Journal of clinical medicine · 2024Article
- Association between Gout and Gastric Cancer: A Nested Case-Control Study Using a National Health Sample Cohort.Journal of personalized medicine · 2024Article
- Association between serum uric acid and colorectal cancer risk in European population: a two-sample Mendelian randomization study.Frontiers in oncology · 2024Article
- Causal relationship between genetic-predicted uric acid and cervical cancer risk: evidence for nutritional intervention on cervical cancer prevention.Frontiers in nutrition · 2024Article
- Targeting Neutrophil Extracellular Traps in Gouty Arthritis: Insights into Pathogenesis and Therapeutic Potential.Journal of inflammation research · 2024Review
- Article
- Investigating the Anti-inflammatory Effect of Allopurinol on the Prevention of Prostate Cancer.Cureus · 2023Article
- Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean.Journal of rheumatic diseases · 2023Review
- The Good, the Bad and the New about Uric Acid in Cancer.Cancers · 2022Review
- Cancer risk in Korean patients with gout.The Korean journal of internal medicine · 2022Article
- Tumor distribution affects bladder recurrence but not survival outcome of multifocal upper tract urothelial carcinoma treated with radical nephroureterectomy.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsUsing a nationwide cohort, we investigated the cancer risk in Korean patients with gout.
methodsData were obtained from the Korean National Health Insurance Service Database. Patients with gout were defined as those aged ≥ 20 years who were diagnosed with gout and received anti-gout medication (allopurinol, colchicine, and benzbromarone) between 2008 and 2010. Patients with nail disorders were randomly assigned to a control group (1:1 ratio) after frequency matching for age and sex. Cancer incidence was then investigated between 2012 and 2018. Cox proportional hazard regression analysis was used to investigate the association between gout and cancer after adjusting for concomitant diseases.
resultsThis study included 179,930 patients with gout and an equal number of matched controls. The incidence of overall cancer was higher in patients with gout than in controls (incidence rate ratio, 1.08). Cox proportional hazards regression analysis showed that gout was associated with a hazard ratio of 1.053 (95% confidence interval ,1.031 to 1.077) after adjusting for concomitant diseases.
conclusionGout was associated with a significantly high risk of cancer, especially esophageal, stomach, colon, liver, pancreatic, lung, ovarian, renal, and bladder cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.